1. Home
  2. BBIO vs BWA Comparison

BBIO vs BWA Comparison

Compare BBIO & BWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • BWA
  • Stock Information
  • Founded
  • BBIO 2015
  • BWA 1987
  • Country
  • BBIO United States
  • BWA United States
  • Employees
  • BBIO N/A
  • BWA N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • BWA Auto Parts:O.E.M.
  • Sector
  • BBIO Health Care
  • BWA Consumer Discretionary
  • Exchange
  • BBIO Nasdaq
  • BWA Nasdaq
  • Market Cap
  • BBIO 5.6B
  • BWA 6.6B
  • IPO Year
  • BBIO 2019
  • BWA 1993
  • Fundamental
  • Price
  • BBIO $36.85
  • BWA $29.49
  • Analyst Decision
  • BBIO Strong Buy
  • BWA Buy
  • Analyst Count
  • BBIO 12
  • BWA 15
  • Target Price
  • BBIO $52.27
  • BWA $40.46
  • AVG Volume (30 Days)
  • BBIO 2.7M
  • BWA 2.6M
  • Earning Date
  • BBIO 02-20-2025
  • BWA 02-06-2025
  • Dividend Yield
  • BBIO N/A
  • BWA 1.49%
  • EPS Growth
  • BBIO N/A
  • BWA N/A
  • EPS
  • BBIO N/A
  • BWA 1.50
  • Revenue
  • BBIO $221,902,000.00
  • BWA $14,086,000,000.00
  • Revenue This Year
  • BBIO $2,306.75
  • BWA $3.34
  • Revenue Next Year
  • BBIO N/A
  • BWA $5.27
  • P/E Ratio
  • BBIO N/A
  • BWA $19.65
  • Revenue Growth
  • BBIO 2285.27
  • BWA N/A
  • 52 Week Low
  • BBIO $21.62
  • BWA $28.65
  • 52 Week High
  • BBIO $39.47
  • BWA $38.23
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 63.77
  • BWA 39.26
  • Support Level
  • BBIO $35.36
  • BWA $28.65
  • Resistance Level
  • BBIO $39.47
  • BWA $30.49
  • Average True Range (ATR)
  • BBIO 1.93
  • BWA 0.99
  • MACD
  • BBIO 0.26
  • BWA -0.02
  • Stochastic Oscillator
  • BBIO 70.79
  • BWA 19.40

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2023, 25% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

Share on Social Networks: